Search clinical trials for: Rosiglitazone Extended Release 8mg

Total 1081 results

GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)

Alzheimer's Disease

United States, Germany, France, Poland, Portugal, Spain, Canada, Argentina, Chile, India, Greece, Hungary, Italy, Japan, Austria, Brazil, Czechia, Mexico, Switzerland
GlaxoSmithKline

Completed

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

Alzheimer's Disease

Germany
GlaxoSmithKline

Terminated

Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

Alzheimer's Disease

United Kingdom
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Methodist Healthcare

Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Recipients of Liver Transplant

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Zogenix, Inc.

Completed

A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

Postoperative Pain
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Dr. Reddy's Laboratories Limited

Completed

A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules

Rosacea

Germany
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Johns Hopkins University
Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple University

Not yet recruiting

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma | Overweight and Obesity | Asthma Chronic
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada
University of Michigan
Food and Drug Administration (FDA)

Recruiting

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

Human Gastrointestinal Physiology Data

United States
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
GlaxoSmithKline

Completed

Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

Type 2 Diabetes Mellitus
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

Healthy

United States
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Healthy

United States
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease
McMaster University

Completed

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Insomnia | Hot Flashes | Major Depressive Disorder

Canada
GlaxoSmithKline

Completed

A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

China
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain

Low Back Pain
Université de Montréal
Labopharm Inc.; MDS Pharma Services

Completed

PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects

Pain | Aging
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

Healthy

United States
Luye Pharma Group Ltd.
Parexel

Completed

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Parkinson Disease

China
National Cheng-Kung University Hospital

Completed

Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease

Coronary Artery Disease | Insulin Resistance | Glucose Intolerance | Prediabetes
University of Colorado, Denver

Withdrawn

Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia

Trigeminal Neuralgia
Beijing Anzhen Hospital
Novartis

Unknown

Fluvastatin AmelIorates aTHerosclerosis Study (FAITH)

Atherosclerosis | Coronary Heart Disease

China
GlaxoSmithKline

Completed

Avandamet Bioequivalence Study Brazil - Fed Administration

Diabetes Mellitus, Type 2

Brazil
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease

China

3

Subscribe